Sensydia
Sensydia is developing the Cardiac Performance System (CPS), a non-invasive, point-of-care hemodynamic measurement platform designed to advance cardiovascular and critical patient care. The CPS platform aims to deliver accuracy equivalent to gold-standard measures through an automated, wireless system. It enables rapid assessment of key metrics like Ejection Fraction (EF) and Cardiac Output (CO), with future capabilities for automatic cardiac abnormality detection. The system is designed for ease of use in hospitals (ICU, ER, bedside) and medical offices, facilitating earlier detection and better management of heart failure, sepsis, and other critical cardiovascular conditions, ultimately reducing readmissions and healthcare costs. The company has invested nearly a decade in research and development, with the Ejection Fraction (EF) metric having FDA approval in 2018. Sensydia has secured funding from the NIH, including a second phase of a $3M grant to support clinical utility studies of the CPS.
Sensydia
Sensydia is developing the Cardiac Performance System (CPS), a non-invasive, point-of-care hemodynamic measurement platform designed to advance cardiovascular and critical patient care. The CPS platform aims to deliver accuracy equivalent to gold-standard measures through an automated, wireless system. It enables rapid assessment of key metrics like Ejection Fraction (EF) and Cardiac Output (CO), with future capabilities for automatic cardiac abnormality detection. The system is designed for ease of use in hospitals (ICU, ER, bedside) and medical offices, facilitating earlier detection and better management of heart failure, sepsis, and other critical cardiovascular conditions, ultimately reducing readmissions and healthcare costs. The company has invested nearly a decade in research and development, with the Ejection Fraction (EF) metric having FDA approval in 2018. Sensydia has secured funding from the NIH, including a second phase of a $3M grant to support clinical utility studies of the CPS.